tiprankstipranks
Trending News
More News >
Citius Oncology (CTOR)
NASDAQ:CTOR
US Market
Advertisement

Citius Oncology (CTOR) AI Stock Analysis

Compare
115 Followers

Top Page

CTOR

Citius Oncology

(NASDAQ:CTOR)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
Citius Oncology's stock score reflects significant financial challenges and bearish technical indicators, offset slightly by its low P/E ratio suggesting potential undervaluation. The absence of revenue and consistent net losses underscore a high-risk profile typical of an early-stage pharmaceutical company. Technical indicators point to negative momentum, while the valuation presents a more optimistic perspective due to the low P/E ratio.
Positive Factors
Innovative Product Pipeline
The company's focus on innovative cancer therapies positions it well for long-term growth, leveraging advanced R&D to address unmet medical needs.
Strategic Partnerships
Strategic partnerships enhance market reach and provide additional revenue streams through licensing and milestone payments, supporting long-term growth.
No Debt
Operating without debt reduces financial risk, providing flexibility to invest in R&D and strategic initiatives without the burden of interest payments.
Negative Factors
Consistent Net Losses
Ongoing net losses reflect financial instability, posing challenges to achieving profitability and requiring sustained external funding for operations.
Negative Free Cash Flow
Negative free cash flow suggests the company struggles to generate cash from operations, potentially hindering its ability to fund growth and innovation.
Volatile Balance Sheet
Volatility and negative equity in the balance sheet indicate financial vulnerability, potentially impacting the company's ability to secure future financing.

Citius Oncology (CTOR) vs. SPDR S&P 500 ETF (SPY)

Citius Oncology Business Overview & Revenue Model

Company DescriptionCitius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
How the Company Makes MoneyCitius Oncology makes money primarily through the research, development, and commercialization of its cancer treatment drugs. The company's revenue streams include licensing agreements, where it partners with other pharmaceutical companies to co-develop or distribute its products, and sales of approved therapies. Additionally, Citius Oncology may receive milestone payments and royalties from partnerships and collaborations with other entities in the healthcare sector. The company's earnings are influenced by the successful clinical trials and regulatory approval of its drug candidates, as well as strategic partnerships that enhance its market reach.

Citius Oncology Financial Statement Overview

Summary
Citius Oncology's financial performance indicates significant challenges, typical of a pharmaceutical company in development stages. The absence of revenue and consistent net losses highlight a high-risk profile. The balance sheet shows volatility with negative equity in some periods, and cash flow statements reveal liquidity challenges and reliance on financing activities.
Income Statement
35
Negative
Citius Oncology shows a challenging income situation with consistent net losses over the reported periods. The absence of revenue and gross profit highlights the early-stage nature or restructuring phase of the company. Despite some improvement in EBIT from 2023 to 2024, the overall profitability metrics remain weak, given the negative net income.
Balance Sheet
45
Neutral
The balance sheet reveals high volatility with fluctuating stockholders' equity and liabilities. Although there is a significant increase in assets from 2023 to 2024, the negative equity in some periods and inconsistent asset base pose stability concerns. The absence of debt could indicate cautious financing, but the negative equity ratios in some periods showcase financial vulnerability.
Cash Flow
40
Negative
Cash flow statements show inconsistent operating cash flows and negative free cash flow, indicating liquidity challenges. The reliance on financing activities to support cash flows is evident, but the lack of consistent positive cash flow from operations could hinder growth prospects. The free cash flow growth rate is negative, which poses a risk for future financial health.
BreakdownTTMDec 2024Dec 2023Dec 2022
Income Statement
Total Revenue0.000.000.000.00
Gross Profit0.000.000.000.00
EBITDA-20.28M-20.57M-12.12M-4.86M
Net Income-25.98M-21.15M-12.70M-5.43M
Balance Sheet
Total Assets91.44M84.37M47.73M42.69M
Cash, Cash Equivalents and Short-Term Investments112.00112.000.000.00
Total Debt3.80M3.80M0.000.00
Total Liabilities55.80M38.23M22.20M6.42M
Stockholders Equity35.64M46.14M25.54M36.27M
Cash Flow
Free Cash Flow-364.06K-4.87M-601.30K-47.97K
Operating Cash Flow-364.06K126.35K-601.30K-47.97K
Investing Cash Flow-27.55K-5.00M-1.32M-67.32M
Financing Cash Flow358.53K4.87M1.66M67.66M

Citius Oncology Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.03
Price Trends
50DMA
1.87
Positive
100DMA
1.91
Positive
200DMA
1.45
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
59.25
Neutral
STOCH
69.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTOR, the sentiment is Positive. The current price of 2.03 is above the 20-day moving average (MA) of 1.87, above the 50-day MA of 1.87, and above the 200-day MA of 1.45, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 59.25 is Neutral, neither overbought nor oversold. The STOCH value of 69.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTOR.

Citius Oncology Risk Analysis

Citius Oncology disclosed 51 risk factors in its most recent earnings report. Citius Oncology reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Citius Oncology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (68)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$80.32B18.3418.84%4.13%3.46%-13.29%
74
Outperform
$20.31B13.259.76%3.48%31.44%
63
Neutral
$8.51B20.482.67%1.45%10.05%98.22%
58
Neutral
$2.69B3.8495.50%5.80%-1.02%-30.57%
47
Neutral
$167.03M16.70-34.78%
68
Neutral
$18.00B11.429.92%3.81%9.73%1.22%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CTOR
Citius Oncology
2.03
0.68
50.37%
BIIB
Biogen
138.52
-52.28
-27.40%
GSK
GlaxoSmithKline
41.10
2.53
6.56%
GRFS
Grifols SA
9.93
1.22
14.01%
SCLX
Scilex Holding Company
26.62
-4.50
-14.46%
OGN
Organon
10.35
-7.74
-42.79%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025